G

Genfit SA
PAR:GNFT

Watchlist Manager
Genfit SA
PAR:GNFT
Watchlist
Price: 4.65 EUR -4.12%
Market Cap: 232.5m EUR

Wall Street
Price Targets

GNFT Price Targets Summary
Genfit SA

Wall Street analysts forecast GNFT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GNFT is 8.86 EUR with a low forecast of 8.08 EUR and a high forecast of 9.45 EUR.

Lowest
Price Target
8.08 EUR
74% Upside
Average
Price Target
8.86 EUR
90% Upside
Highest
Price Target
9.45 EUR
103% Upside
Genfit SA Competitors:
Price Targets
LCTX
Lineage Cell Therapeutics Inc
130% Upside
EXAS
Exact Sciences Corp
0% Downside
INSM
Insmed Inc
7% Upside
0HS8
Caladrius Biosciences Inc
526% Upside
CNTB
Connect Biopharma Holdings Ltd
236% Upside
VTGN
VistaGen Therapeutics Inc
242% Upside
GYRE
Gyre Therapeutics Inc
130% Upside
BIOCON
Biocon Ltd
13% Upside

Revenue
Forecast

Revenue Estimate
Genfit SA

For the last 13 years the compound annual growth rate for Genfit SA's revenue is 20%. The projected CAGR for the next 3 years is -6%.

20%
Past Growth
-6%
Estimated Growth
Estimates Accuracy
24%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Genfit SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat

Net Income
Forecast

Net Income Estimate
Genfit SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-40%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is GNFT's stock price target?
Price Target
8.86 EUR

According to Wall Street analysts, the average 1-year price target for GNFT is 8.86 EUR with a low forecast of 8.08 EUR and a high forecast of 9.45 EUR.

What is Genfit SA's Revenue forecast?
Projected CAGR
-6%

For the last 13 years the compound annual growth rate for Genfit SA's revenue is 20%. The projected CAGR for the next 3 years is -6%.

Back to Top